|
|
Heterologous Expression, Purification and Aggregation Characterization of Tau Core Fragment 306-378 |
WEI Wei,CHANG Bao-gen,WANG Ying,LU Fu-ping(),LIU Fu-feng() |
Key Laboratory of the Ministry of Education of Industrial Fermentation Microorganisms, Tianjin Key Laboratory of Industrial Microbiology, National Engineering Laboratory of Industrial Enzymes, School of Bioengineering, Tianjin University of Science and Technology, Tianjin 300457, China |
|
|
Abstract Tau is one of the microtubule-associated proteins. Its physiological function is to promote microtubule assembly and maintain microtubule stability. The phosphorylated Tau easily aggregated and subsequently caused a series of tauopathies. Of them, Alzheimer's disease is a common type of tauopathies. Six subtypes of Tau are also found in human brain because of different mRNA splicing of the same gene. They are respectively composed of 352, 381, 383, 410, 412 and 441 residues. The molecular weight of the six subtypes is among 48-67kDa, the R1, R2, R3 and R4 are the microtubule binding domains, which can bind to microtubule and maintain microtubule stability. Compared with the full-length Tau, the truncated Tau isoforms, such as R1-R4, are more likely to aggregate and have stronger aggregation kinetics. For example, the microtubule binding domain of R3 and R4 and the following 10 amino acid at the C-terminal of R4 sequence are the core peptide of the paired helical fibrils (PHFs), which has been proven to drive Tau aggregation. And its fibrillary 3D structure was also identified using micro-electron diffraction of Cryo-electron microscope. Herein, the core fragment 306-378 (Tau306-378) of Tau was heterogeneously expressed in Escherichia coli, and the purified Tau306-378 was obtained by Ni+ chelated affinity chromatography. The final production yield was about 10.35mg/L. Then, the results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot proved that Tau306-378 was expressed successfully. Moreover, the matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was further used to confirm the molecular weight of Tau306-378. It was proved that most of the Tau306-378 were in the form of monomers. In addition, a small portion of dimers were also found in the protein sample, which is caused by the formation of disulfide bond among two monomers. In order to explorethe effect of induction temperature on the production of the target protein, four different induction temperatures (16℃, 25℃, 30℃ and 37℃) were investigated. The results showed that the expression of Tau306-378 was the highest at 30℃, followed by 25℃ and 16℃. However, the expression of Tau306-378 was the lowest at 37℃. The optimal inducing condition of Tau306-378 were identified: inducing at 30℃ for 16-20h with 0.5mmol/L of isopropyl-β-D-thiogalactopyranoside. Finally, thioflavin T fluorescence staining experiments were performed to probe its fibrillogenesis. The results of thioflavin T fluorescence experiments showed that the trend of aggregation dynamics presents a typical S-shaped curve. That is, the recombinant Tau306-378 has good aggregation characteristics, which could be used to study the aggregation characteristics and toxicity of Tau in vitro, as well as in the screening of various inhibitors against Tau fibrillogenesis.
|
Received: 20 November 2019
Published: 02 June 2020
|
|
Corresponding Authors:
Fu-ping LU,Fu-feng LIU
E-mail: fplu302@mail.tust.edu.cn;fufengliu@tust.edu.cn
|
|
|
[1] |
Fitzpatrick A, Falcon B, He S , et al. Cryo-EM structures of Tau filaments from Alzheimer's disease brain. Nature, 2017,547(7662):185-190.
|
|
|
[2] |
Hardy J . Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. Journal of Alzheimers Disease, 2006,9(S3):151-153.
|
|
|
[3] |
Rossor M N . Molecular pathology of Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry, 1993,56(6):583-586.
|
|
|
[4] |
Yankner B A, Duffy L K, Kirschner D A . Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 1990,250(4978):279-282.
|
|
|
[5] |
Wang Y, Mandelkow E . Tau in physiology and pathology. Nature Reviews Neuroscience, 2016,17(1):5-21.
|
|
|
[6] |
Liu F F, Dong X Y, He L Z , et al. Molecular insight into conformational transition of amyloid beta-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations. Journal of Physical Chemistry B, 2011,115(41):11879-11887.
|
|
|
[7] |
Kametani F, Hasegawa M . Reconsideration of amyloid hypothesis and Tau hypothesis in Alzheimer's disease. Frontiers in Neuroscience, 2018,12(25):1-11.
|
|
|
[8] |
Brier M R, Gordon B, Friedrichsen K , et al. Tau and abeta imaging, CSF measures, and cognition in Alzheimer's disease. Science Translational Medicine, 2016,8(338):338ra366.
|
|
|
[9] |
Shammas S L, Garcia G A, Kumar S , et al. A mechanistic model of Tau amyloid aggregation based on direct observation of oligomers. Nature Communications, 2015,6(1):1-10.
|
|
|
[10] |
Mandelkow E M, Mandelkow E . Tau protein and Alzheimer's disease. Neurobiology of Aging, 1994,15(1):85-86.
|
|
|
[11] |
Rademakers R, Cruts M, van Broeckhoven C . The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Human Mutation, 2010,24(4):277-295.
|
|
|
[12] |
Verwilst P, Kim H S, Kim S , et al. Shedding light on Tau protein aggregation: the progress in developing highly selective fluorophores. Chemical Society Reviews, 2018,47(7):2249-2265.
|
|
|
[13] |
Seidler P M, Boyer D R, Rodriguez J A , et al. Structure-based inhibitors of Tau aggregation. Nature Chemistry, 2018,10(2):170-176.
|
|
|
[14] |
Bratus S, Pak I . Structure, microtubule interactions, and paired helical filament aggregation by Tau mutants of frontotemporal dementias. Biochemistry, 2000,39(38):11714-11721.
doi: 10.1021/bi000850r
|
|
|
[15] |
Hasegawa M, Smith M J, Goedert M . Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. Febs Letters, 1998,437(3):207-210.
|
|
|
[16] |
Karikari T K, Turner A, Stass R , et al. Expression and purification of Tau protein and its frontotemporal dementia variants using a cleavable histidine tag. Protein Expression and Purification, 2016,130:44-54.
|
|
|
[17] |
Michel C H, Kumar S, Pinotsi D , et al. Extracellular monomeric Tau protein is sufficient to initiate the spread of Tau protein pathology. Journal of Biological Chemistry, 2013,289(2):956-967.
doi: 10.1074/jbc.M113.515445
|
|
|
[18] |
Yao T M, Tomoo K, Ishida T , et al. Aggregation analysis of the microtubule binding domain in Tau protein by spectroscopic methods. Journal of Biochemistry, 2003,134(1):91-99.
|
|
|
[19] |
Barghorn S, Davies P, Mandelkow E . Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on β-structure in the core domain. Biochemistry, 2004,43(6):1694-1703.
|
|
|
[20] |
Jia L G, Wang W J, Shang J Z , et al. Highly efficient soluble expression, purification and characterization of recombinant Aβ42 from Escherichia coli. Rsc Advances, 2018,8(33):18434-18441.
|
|
|
[21] |
Du W J, Guo J J, Gao M T , et al. Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. Scientific Reports, 2015,5(1):1-10.
|
|
|
[22] |
Jia L G, Wang W J, Sang J C , et al. Amyloidogenicity and cytotoxicity of a recombinant C-terminal His-Tagged Aβ. Acs Chemical Neuroscience, 2019,10(3):1251-1262.
|
|
|
[23] |
Li S, Liu F F, Yu L L , et al. Dual effect of thioflavin T on the nucleation kinetics of amyloid β-protein 40. Acta Physico-Chemica Sinica, 2016,32(6):1391-1396.
|
|
|
[24] |
Kundel F, De S, Flagmeier P , et al. Hsp70 inhibits the nucleation and elongation of Tau and sequesters Tau aggregates with high affinity. Acs Chemical Biology, 2018,13(3):636-646.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|